Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial
Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H. pylori eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one. Methods. This randomized...
Saved in:
Main Authors: | Masafumi Maruyama, Naoki Tanaka, Daisuke Kubota, Masayuki Miyajima, Takefumi Kimura, Koujiro Tokutake, Ryujiro Imai, Toru Fujisawa, Hiromitsu Mori, Yoshiaki Matsuda, Shuichi Wada, Akira Horiuchi, Kendo Kiyosawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Canadian Journal of Gastroenterology and Hepatology |
Online Access: | http://dx.doi.org/10.1155/2017/4385161 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
by: Soichiro Sue, et al.
Published: (2017-01-01) -
Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
by: Soichiro Sue, et al.
Published: (2018-01-01) -
Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
by: Davide Giuseppe Ribaldone, et al.
Published: (2018-01-01) -
The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials
by: Ting Jin, et al.
Published: (2025-01-01) -
Analyses of poverty indicators using PPI methodology
by: T. Merkulova, et al.
Published: (2024-06-01)